Monitor for additional selling in the next 30 days, while this cluster is within normal range, concentrated C-suite selling could become a concern if it continues. No immediate negative signal, but watch for changes in trading patterns ahead of earnings or clinical updates.
QURE drugs
QURE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 25 $24.87entry
- T+1 · 9mo ago −31.18%α −30.64% · $17.12
- T+5 · 9mo ago −63.65%α −62.55% · $9.04
- T+20 · 8mo ago −34.22%α −28.98% · $16.36
- T+60 · 6mo ago −1.09%α −8.04% · $24.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two top executives at uniQure, the CEO and CFO, sold shares in a coordinated open-market transaction, generating nearly $444,000 in proceeds. The sales represent a modest dollar amount relative to the company's $1.1B market cap and appear to be routine portfolio management rather than a signal of distress.
Key Financial Metrics
Key Facts
- CEO Matthew Kapusta sold 12,378 shares for $295,339 in an open-market transaction.
- CFO Christian Klemt sold 6,217 shares for $148,338 in an open-market transaction.
- Both sales occurred on the same day at the same price ($23.86).
- Total value of the cluster: $443,677, representing approximately 0.04% of uniQure's $1.1B market cap.
Financial Impact
$443,677 in insider selling over a 7-day window
Risk Factors
- Perception risk from coordinated C-suite selling, even if routine.
- Potential for negative sentiment if no offsetting buy-side activity follows.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (2 trades, 7d window) | cluster-QURE-1772229019704 |
Track record
38 reports on QURE
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers